Palbociclib in the treatment of recurrent ovarian cancer
Serous ovarian cancers are typically high grade and recur within a short interval. The currently available therapeutic options provide a relatively low response rate and the progress-free survival are short-lived. There is emerging data that CDK4/6 may be effective in metastatic ovarian cancer. This...
Saved in:
Main Authors: | Dai Wee Lee (Author), Gwo Fuang Ho (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Palbociclib in breast cancer neoadjuvant setting
by: Sílvia Alexandra Cabral Duarte, et al.
Published: (2021) -
Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
by: Chenxin Duan, et al.
Published: (2021) -
A promising response of refractory uterine leiomyosarcoma to pembrolizumab and temozolomide combination therapy
by: Rebecca Lin, et al.
Published: (2024) -
CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB - A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
by: E. N. Imyanitov, et al.
Published: (2017) -
Palbociclib in metastatic breast cancer: current evidence and real-life data
by: Francesco Serra, et al.
Published: (2019)